BioNTech SE (BNTX) Cost of Revenue (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Cost of Revenue data on file, last reported at $388.0 million in Q4 2025.

• In Q4 2025, Cost of Revenue rose 49.11% year-over-year to $388.0 million; the TTM figure through Dec 2025 stood at $736.0 million (up 25.75% YoY), while the FY2025 annual figure was $725.1 million, up 25.36% from the prior year.
• Cost of Revenue climbed to $388.0 million in Q4 2025, from $173.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.5 billion in Q1 2022 and bottomed at $667.16 in Q4 2021.
• A 5-year average of $336.0 million and a median of $188.4 million in 2021 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2021 — Cost of Revenue jumped 4316954698.55% — and 2023, when it slumped 92.91%.
• Year by year, Cost of Revenue stood at $667.16 in 2021, then surged by 28061280.89% to $187.2 million in 2022, then rose by 2.93% to $192.7 million in 2023, then surged by 35.03% to $260.2 million in 2024, then surged by 49.11% to $388.0 million in 2025.
• The last three Cost of Revenue figures came in at $388.0 million (Q4 2025), $173.4 million (Q3 2025), and $86.5 million (Q2 2025), per Business Quant data.

Peer Comparison